Skip to main content

As of January 12, 2016 Microsoft announced the end of support for IE10, IE9 and IE8. Mainstream support for IE11 officially ended in November of 2020 as Microsoft announced they will drop support across Microsoft 365 apps in August of 2021.

Please consider using an alternative browser such as Chrome, Firefox, or Safari.

Spotlight On

James P. Franciosi

M.D., M.S., M.S.C.E., F.A.A.P.

M.D., M.S., M.S.C.E., F.A.A.P. | Chief, Division of Gastroenterology, Hepatology and Nutrition | Professor of Pediatrics | Orlando | Nemours Children's Health System

James P. Franciosi

M.D., M.S., M.S.C.E., F.A.A.P.

Over the last twelve years, I have had the privilege to care for children and teens with Eosinophilic Esophagitis and Eosinophilic GI Diseases (EGID).  Our mission is to find ways to reduce the burden of EoE and EGID and to speed advances and innovations for the patients who need them.  

My background includes extensive training in general pediatrics and pediatric gastroenterology at the Children's Hospital of Philadelphia, Cincinnati Children's Hospital Medical Center, and Nemours Children's Hospital. Currently, I serve as the Division Chief for the Division of Gastroenterology, Hepatology, and Nutrition at Nemours Children's Hospital in Orlando, Florida.  Our team has written over sixty peer-reviewed publications, has presented our research at national and international meetings, and has had multiple externally funded grants.  We developed the first validated outcome metrics for EoE called the PedsQLEoE module and the Pediatric Eosinophilic Esophagitis (EoE) Symptom Score (PEESS v2.0).  We dedicate ourselves to bringing advances to the field of pediatric EoE.  Specifically, our center has launched a successful transnasal esophagoscopy program (TNE), and we currently use the Endoflip device.  Our forward-thinking approach and pioneering spirit fuel our advancement in EoE research and drive and inspire us to understand the disease in the patient and not just in their EoE journey.

We are currently conducting a novel Food Additive Removal Diet for EoE.  Dr. Ed Mougey and I have been working together in the area of PPI pharmacogenomics and clinical outcomes.  Building on our prior work with Proton Pump Inhibitor medications, we discovered novel CYP2C19 and STAT6 genetic variants that may, in part, explain the inter-individual variability in response to PPI medications.  Our longer-term goal is to identify additional genetic predictors of PPI therapy response at EoE diagnosis before patients begin treatment so that treatment adjustments can be made to maximize the probability of response to PPI therapy.


May, 1996 Marquette University, Milwaukee, WI, B.S.

July, 1992 Trinity College, Hartford, CT,

Graduate/Medical School:

May, 2008 University of Pennsylvania, Philadelphia, PA, 2006-2008, M.S.C.E

May, 2001 Medical College of Wisconsin, Milwaukee, WI, 1996-2001, M.D.

May, 2000 Medical College of Wisconsin, Milwaukee, WI, 1996-1999, M.S.


2003-2004 Intern in Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA


2005-2008 Clinical Fellow, Pediatric Gastroenterology, Hepatology & Nutrition, The Children’s Hospital of Philadelphia, Philadelphia, PA.

2004-2005 Resident in Pediatrics, (ABP Special Alternative Pathway) The Children’s Hospital of Philadelphia, Philadelphia, PA.

2001-2003 Resident in General Surgery, Parkland Hospital, University of Texas Southwestern, Dallas, TX.

  • Aerodigestive Tract Disorders
  • Gastroenterology (Digestive Health)
  • Inflammatory Bowel Disease (IBD)
  • Eosinophilic Esophagitis
  • Unsedated Transnasal Endoscopy


  1. 08/01/2018-07/31/2020
    • Transnasal Esophagoscopy: Programmatic Development
    • Funds: $250,000
    • Role: PI
  2. 09/15/2018-09/14/2020 - PPIREE Research, Anonymous External Donor 200,000

Role: PI

3. 12/31/2017-12/31/2020 - FREE: EoE Research, Anonymous External Donor $450,000

Role: PI

4. 07/01/2016-06/30/2019 - Thrasher Research Fund, Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children with Uncontrolled Asthma (GenARA) $383,242 (0.48 calendar months) Lang (PI)

Role: Co-Investigator

5. 05/01/2015-04/30/2016 - Patient Centered Outcomes Research Institute (PCORI), A National Pediatric Learning Health System, R-1306-01556 $7,000,000 Forrester (PI)

Role: Co-Investigator

6. 02/19/2014 –02/18/2015 - Nemours Biomedical Research Foundation, PPI Epidemiology, Adverse Events and Efficacy Associated with CYP2C19 $20,719

Role: PI

7. 04/15/2014 –04/14/2015 - Nemours Biomedical Research Foundation, CYP2C19 Metabolizer Phenotypes using Saliva and Esophageal Biopsy Samples $12,361

Role: PI

8. 09/15/2017-09/14/2018 - PPIREE Research, Esophageal Programmatic Development Fund $100,000

Role: PI

9. 07/01/2015-09/14/2018 - Nemours Biomedical Research Foundation,Implementation of PGX testing $88,784.37 Lima (PI)

Role: Co-Investigator

10. 05/01/2016-4/30/2017 - NIH, Genomic Medicine Implementation: The Personalized Medicine Program $199,581 Johnson (PI)

Role: Co-Investigator; Franciosi site & sub-study (PI)

11. 09/15/13-09/14/16 - US Army Medical Research Acquisition Activity Maintenance of health care providers’ clinical proficiency: Transdisciplinary analysis, modeling and intervention W81XWH-13-1-0316 $3,936,682 Wysocki (PI)

Role: Co-Investigator

12. 8/2011-9/2012 - AGA Esophageal Disease Award, Long-term Pediatric Eosinophilic Esophagitis Therapies: Are We Causing Harm? $35,000

Role: PI

13. 09/30/09 – 08/31/11 - NIH/NIDDK, Eosinophilic Esophagitis Comparative Effectiveness R01 DK076893-03S1 $1,045,941 Rothenberg (PI)

Role: Co-Investigator

14. 12/15/08 – 06/30/11 - Young Investigator Award, Children’s Digestive Health and Nutrition Foundation, Outcome Measures in Eosinophilic Esophagitis $75,000

Role: PI

15. 08/2009 – 08/2010 UCB Pharmaceuticals, The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents (NURTURE) Study

Role: PI


Questions? We are here to help!

Click the link below for additional resources or email us at